Form D · Biotechnology
NEPHRX CORP
Kalamazoo, MI · CIK 0001171421
Offering snapshot reported Feb 10, 2010 · SEC filing
- Reported sold
- $6.22M Offering amount: $6.22M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $41 Reported outside-investor minimum
- First sale
- Nov 15, 2007 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 10, 2010 | Amendment | $6,219,317 | No comparison | 12 | SEC filing |
| Dec 3, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06, 3C, 3C.1
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-55551
Source: Form D, filed Feb 10, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Cox | Director |
| Charles Hall | Director |
| James Koziarz | Director |
| Elizabeth Long | Executive |
| Phillip Long | Director |
| William Mc Ginnis | Executive |
| Patrick Morand | Director |
| Douglas Morton | Director |
| Donald Parfet | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4717 Campus Drive
Kalamazoo, MI, 49008
Kalamazoo, MI, 49008